Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM).
Despite their efficacy, most patients develop resistance, and the mechanisms are not fully …

Recent therapeutic advances have significantly improved the outcome for patients with
multiple myeloma (MM). The backbone of successful standard therapy is the combination of …

Among blood cancers, multiple myeloma (MM) represents the second most common
neoplasm and is characterized by the accumulation and proliferation of monoclonal plasma …

Multiple myeloma (MM) is an incurable plasma cell malignancy that exploits transcriptional
networks driven by IRF4. We employ a multi-omics approach to discover IRF4 …

Abstract Purpose: Immunomodulatory drugs (IMiDs), such as lenalidomide and
pomalidomide, are a cornerstone of multiple myeloma (MM) therapies, yet the disease …

Immunocompetent murine models of multiple myeloma are critical for understanding the
pathogenesis of multiple myeloma and for the development of novel immunotherapeutics …

Cereblon-targeting degraders, such as immunomodulatory imide drugs (IMiDs)
lenalidomide and pomalidomide and their derivative cereblon E3 ligase modulators (CEL …

In this issue of Blood Cancer Discovery, Neri, Barwick, and colleagues and Welsh, Barwick,
and colleagues performed RNA sequencing, chromatin immunoprecipitation sequencing …

Organismal aging has been associated with diverse metabolic and functional changes
across tissues. Within the immune system, key features of physiological hematopoietic cell …

Background: high-altitude work exposes individuals to reduced oxygen levels, imposing
physi-ological adaptations. These conditions can induce alterations in the cardiovascular …